Cetera Investment Advisers’s Ocular Therapeutix OCUL Stock Holding History

Cetera Investment Advisers’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,000	Closed	-$11K	–	3725
2023 Q4	$11K	Buy	+5,000	New	+$14.8K	﹤0.01%	2204
2023 Q3	–	Sell	-15,000	Closed	-$5.5K	–	2273
2023 Q2	$5.5K	Buy	+15,000	New	+$89.2K	﹤0.01%	2168
2022 Q4	–	Sell	-5,000	Closed	-$3K	–	2153
2022 Q3	$3K	Buy	+5,000	New	+$25.2K	﹤0.01%	1687
2022 Q1	–	Sell	-10,000	Closed	-$19K	–	1964
2021 Q4	$19K	Buy	+10,000	New	+$77.7K	﹤0.01%	1838

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cetera Investment Advisers's OCUL Position: Q1 2026 in Review

Cetera Investment Advisers increased its Ocular Therapeutix (OCUL) stake by 5.8% in Q1 2026, buying an estimated $401K and bringing the position to 764,615 shares worth $6.48M. The position accounts for 0.01% of the portfolio, ranked #1333.

Cetera Investment Advisers first reported a position in OCUL in Q3 2021 and has held it in 19 quarters since. The position peaked at $8.77M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Cetera Investment Advisers held 764,615 shares of Ocular Therapeutix worth $6.48M as of Q1 2026.
Cetera Investment Advisers bought 42,075 Ocular Therapeutix shares in Q1 2026, an estimated $401K.
Ocular Therapeutix made up 0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #1333 holding.
Cetera Investment Advisers first reported a position in Ocular Therapeutix in Q3 2021 and has held it in 19 quarters since.
Cetera Investment Advisers's Ocular Therapeutix position peaked at $8.77M in Q4 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.